TrialJournal of clinical and experimental hematopathology : JCEH

Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.

Dai Maruyama et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.